LDAC

DRUG2 trials

Sponsors

AstraZeneca, Pfizer

Conditions

Acute Myeloid Leukemia

Phase 1

A Study Of PF-04449913 In Japanese Patients With Select Hematologic Malignancies

CompletedNCT02038777

PfizerAcute Myeloid Leukemia

Start: 2014-03-25End: 2023-12-28Updated: 2025-02-26

Phase 2

Study to Investigate the Efficacy, Safety and Tolerability of AZD1152 Alone and in Combination With Low Dose Cytosine Arabinoside (LDAC)in Acute Myeloid Leukaemia (AML) Patients

CompletedNCT00952588

AstraZenecaAcute Myeloid Leukemia

Start: 2009-07-31End: 2011-06-30Updated: 2020-02-24

Related Papers

Glasdegib with intensive/nonintensive chemotherapy in Japanese patients with untreated acute myeloid leukemia or high‐risk myelodysplastic syndromes

Cancer Science2024-02-073 citations

Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia.

2012-10-15175 citations